Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Loading ETF research
Fetching the latest fund profile, holdings, and market data.

Chicago Board Options ExchangeEquity
At close
$35.03
+$0.3097 · +0.89%
Sep 15, 3:59 PM ET
Regular session · ET · Market data may be delayed.
GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies.The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development.Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Otherfactors include supply chain positioning, growth potential, and valuation. Up to 15% may beallocatedto illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.
Fund assets
2.6M USD
Expense ratio
0.35%
NAV
$34.70
Average volume
1.45K
Volume
334
Day range
$34.99 – $35.03
52-week range
$23.88 – $36.54
Previous close
$34.7203
Price change
1 day
+0.89%
1 month
+9.67%
3 months
+29.93%
Year to date
+36.25%
1 year
+36.25%
3 years
+36.25%
5 years
+36.25%
Price changes exclude distributions, fees, taxes, and investor-specific cash flows.
Portfolio
Holdings data updated Sep 15, 2026.
Portfolio composition
Latest coverage
No ETF news is currently available.
More funds
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.